Sodium equilin 3-monosulfate belongs to the sulfated steroids, a subclass of steroids and steroid derivatives within the organic compounds. This compound has the formula C18H19NaO5S and an average molecular weight of 370.39 g/mol. Biologically, it acts as an antioxidant (PMC4892323) and an agonist (PMC6992541). It has been recorded in sources including household cleaning and consumer products such as pipe accessories, food processing and cookware specifically in the preparation of vinegar, and electrical and electronic equipment including antennas, electric hearing aids, and video games.
The compound is associated with various health effects. It is linked to inflammation (PMC7405951), obesity (PMC2747085, PMC2943125), overweight (PMC8494257), vascular disease (PMC2943125), and intrahepatic cholestasis of pregnancy (PMC9213752). Neurological and psychiatric associations include schizophrenia (PMC8881738), as well as increases in anxiety (PMC12562881) and depression (PMC11157951, PMC12562881). It is also associated with low birth weight (PMC11945857) and osteoporosis (PMC2879572). Regarding oncology, it is associated with cancer (PMC3447581, PMC4422115, PMC7766742), including prostate cancer (PMC8395949), lung cancer (PMC8395949), colorectal cancer (PMC8395949), breast cancer (PMC10901106, PMC2646121, PMC3033239, PMC3662172, PMC3922631, PMC4153070, PMC7766742, PMC8268473), and increases in both prostate cancer (PMC3134227, PMC8026668), ovarian cancer (PMC4602822, PMC7766742), and endometrial cancer (PMC4591525, PMC4783235, PMC8268473), as well as ovarian cancer (PMC7766742).
Therapeutically, sodium equilin 3-monosulfate is used as a treatment for stroke (PMC7766742) and osteoporosis (PMC11036926, PMC7766742, PMC8268473). It has therapeutic effects on depression (PMC12562881) and anxiety (PMC12562881). In clinical observations, it is detected in the blood of individuals with hypogonadism (PMC12562881) and is elevated in the blood in cases of increased prostate cancer (PMC3134227).
